USANA HEALTH SC (USJ MU) stock market data APIs
€15.3069
0(0%)
as of March 18, 2026
Try our APIs with
free plan!
USANA HEALTH SC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for USJ.MU.
Prev. Close
15.3069
Open
15.3069
High
15.3069
Low
15.3069
52 wk Range
15.3-29.6
Market Cap
1 743 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get USANA HEALTH SC data using free add-ons & libraries
Get USANA HEALTH SC Fundamental Data
USANA HEALTH SC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
USANA HEALTH SC News
New
EHC Stock: Do Valuation and Expansion Trends Support a Hold Strategy?
Encompass Health Corporation EHC is a leading provider of inpatient rehabilitation services in the United States, specializing in facility-based patient care through a nationwide network of hospitals....
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-r...
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
The Cigna Group CI, a global health company, continues to offer a variety of health solutions and insurance products. It operates through two key segments — Cigna Healthcare, which provides medical,...
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
Ultragenyx Pharmaceutical RARE reported positive results from a late-stage study of its investigational AAV8 gene therapy, DTX301, for the treatment of ornithine transcarbamylase (OTC) deficiency. Th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
